Received Oct 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
lymphoma; This serious case was reported by a consumer via call center representative and described the occurrence of lymphoma in a elderly female patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received Shingrix. On an unknown date, less than 2 years after receiving Shingrix, the patient experienced lymphoma (Verbatim: lymphoma) (serious criteria GSK medically significant). The outcome of the lymphoma was unknown. It was unknown if the reporter considered the lymphoma to be related to Shingrix. The company considered the lymphoma to be unrelated to Shingrix. Additional Information: GSK receipt date: 16-OCT-2025 The patient received both doses of Shingrix for shingles in 2021 for shingles subsequently to that the patient had to undergo chemotherapy for lymphoma. It had been a couple of years patient's immune system was back and wanted to know if she needed to do the 2 doses again. The reporter did not know if it would be still effective after chemotherapy. Chemotherapy for lymphoma started in winter of 2021 till spring March of 2022. Date of Shingrix vaccine was unknown. The chemotherapy was hopefully done for done. The batch number was not provided upon follow- up with the reporter.; Sender's Comments: A case of Lymphoma, less than 2 years after receiving Shingrix, in an elderly female patient. Based on the available information a?possible causality that the event was caused by the GSK product cannot be ascertained. Consent for further follow-up has not been received.